文献速递血栓与止血

重组人DNase-I通过降解中性粒细胞胞外诱捕网改善急性呼吸窘迫综合征

Recombinant human DNase-I improves acute respiratory distress syndrome via neutrophil extracellular trap degradation.
PubMed 文献 · J Thromb Haemost · 2023-05-16

研究在成年小鼠中经鼻给予聚肌胞苷酸连续3天模拟病毒感染,随机接受静脉安慰剂或重组人DNase-I(rhDNase),并在小鼠和供体人血中评估免疫激活、血小板聚集和凝血。结果显示rhDNase可降解NETs、减轻炎症、减弱血小板活化并正常化凝血时间,改善区域灌注;人血中同样减少NETs和血小板活化。

要点

  • 实验性ARDS中,支气管肺泡灌洗液和缺氧肺组织内可见中性粒细胞胞外诱捕网(NETs)。
  • rhDNase减轻聚肌胞苷酸诱导的细支气管周围、血管周围及间质炎症。
  • rhDNase降解NETs、减少血小板-NET聚集体、降低血小板活化并正常化凝血时间以改善区域灌注。

核心结论

  • 实验性ARDS后,NETs通过为聚集的血小板提供支架加剧炎症并促进异常凝血。
  • 静脉给予rhDNase可降解NETs并减轻ARDS中的凝血障碍,为改善ARDS后肺结构和功能提供有前景的转化方法。

研究设计与样本

  • 成年小鼠经鼻给予聚肌胞苷酸连续3天模拟病毒感染,随机接受静脉安慰剂或rhDNase。
  • 在小鼠和供体人血中评估rhDNase对免疫激活、血小板聚集和凝血的影响。

主要发现

  • 实验性ARDS后,支气管肺泡灌洗液和缺氧肺组织区域观察到NETs。
  • rhDNase减轻聚肌胞苷酸诱导的细支气管周围、血管周围和间质炎症。
  • rhDNase降解NETs,减弱血小板-NET聚集体,减少血小板活化,并正常化凝血时间以改善区域灌注(通过大体形态学、组织学和微计算机断层扫描成像观察)。
  • 在人血中,rhDNase同样减少NETs并减弱血小板活化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Respiratory failure is the primary cause of death in patients with COVID-19, whereas coagulopathy is associated with excessive inflammation and multiorgan failure. Neutrophil extracellular traps (NETs) may exacerbate inflammation and provide a scaffold for thrombus formation. OBJECTIVES: The goal of this study was to determine whether degradation of NETs by recombinant human DNase-I (rhDNase), a safe, Food and Drug Administration-approved drug, reduces excessive inflammation, reverses aberrant coagulation, and improves pulmonary perfusion after experimental acute respiratory distress syndrome (ARDS). METHODS: Intranasal poly(I:C), a synthetic double-stranded RNA, was administered to adult mice for 3 consecutive days to simulate a viral infection, and these subjects were randomized to treatment arms, which received either an intravenous placebo or rhDNase. The effects of rhDNase on immune activation, platelet aggregation, and coagulation were assessed in mice and donor human blood. RESULTS: NETs were observed in bronchoalveolar lavage fluid and within regions of hypoxic lung tissue after experimental ARDS. The administration of rhDNase mitigated peribronchiolar, perivascular, and interstitial inflammation induced by poly(I:C). In parallel, rhDNase degraded NETs, attenuated platelet-NET aggregates, reduced platelet activation, and normalized the clotting time to improve regional perfusion, as observed using gross morphology, histology, and microcomputed tomographic imaging in mice. Similarly, rhDNase reduced NETs and attenuated platelet activation in human blood. CONCLUSION: NETs exacerbate inflammation and promote aberrant coagulation by providing a scaffold for aggregated platelets after experimental ARDS. Intravenous administration of rhDNase degrades NETs and attenuates coagulopathy in ARDS, providing a promising translational approach to improve pulmonary structure and function after ARDS.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Jarrahi A, Khodadadi H, Moore NS, et al. Recombinant human DNase-I improves acute respiratory distress syndrome via neutrophil extracellular trap degradation. J Thromb Haemost. 2023. PMID: 37196848. doi:10.1016/j.jtha.2023.04.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。